Measurement of MMP-9 Expression Level for Treatment Assessment in Breast Cancer Patients
DOI:
https://doi.org/10.22100/jkh.v3i3-4.220Keywords:
Plasma MMP-9 level, Tumor progression, Breast cancerAbstract
Introduction: MMP-9 (matrix metalloproteinase-9) is an enzyme with protease activity the performance of which in creating several cancers has been reported up to now. With respect to the relationship between the active form of this enzyme and occurrence of cancer, in the present study, we decided to assay the plasma level of this enzyme in recuperating or aggravating and metastasis of the breast cancer.
Methods: In this study, MMP-9 activity was measured by gelatin quantitative zymography in the euglobulin plasma of 98 patients in two steps of diagnosis and after treatment of cancer.
Results: From the 80 patients with positive response to treatment, in 76 persons, the MMP-9 significantly decreased after treatment compared to the time of diagnosis. Whereas in 4 patients, the MMP-9 plasma level did not show any change before and after the treatment. Also in 18 patients with recurrence, (6 persons with early breast cancer and 12 persons with metastasis to other tissues) this enzyme level increased, compared with the time of diagnosis.
Conclusion: Our results show a positive correlation between plasma MMP-9 activity and the treatment or metastasis to the other tissues. According to our findings, plasma MMP-9 level can be used as a useful factor for investigating the reaction status of breast cancer patients to the treatment.
References
Crowe DL, Tsang KJ, Shemirani B. Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia 2001;3(1):27-32.
Martinella-Catusse C, Polette M, Noel A, Gilles C, Dehan P, Munaut C, et al. Down-regulation of MT1-MMP expression by the alpha 3 chain of type IV collagen inhibits bronchial tumor cell line invasion. Lab Invest 2001;81(2):167-75.
Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001;13(2):117-23.
Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I, et al. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001;61(1):376-82.
Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61(1):237-42.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-74.
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92(8):827-839.
Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994;269(9):6632-6636.
Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990;9(4):289-303.
Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53(1):140-6.
Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 2005;236(1):125-32.
Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005;116(3):422-7.
Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 2000;20(2B):1307-10.
Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996;24(5):1058-62.
Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17(3C):2253-8.
Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 1997;84(1):133-6.
Sadeghi M, Motovali-Bashi M, Hojati Z. MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. IJIB 2009;6(1): 33-37.
Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M, et al. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 2000;89(4):389-94.
Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffé ED, et al. Circulating 92-Kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck. Cancer Res 2002;36:127-122.
Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001;34(5):347-52.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52.
Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D'Amico DF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 1999;19(5C):4485-90.
Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues:Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212-27.
La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90(7):1414-21.
Mannello F, Tonti GA. Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007;121(1):216-218.
Ferno M. Prognostic factors in breast cancer: A brief review. Anticancer Res 1998;18(3C):2167-71.
Souhami RL, Tannock I, Hohenberger P, Horiot JC. Oxford textbook of oncology. 2nd ed. New York: Oxford University Press; 2002.p.1725-34.
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124(7):966-78.
Hashimoto N, Kobayashi M, Tsuji T. Serum Type IV collagen-degrading enzyme in hepatocellular carcinoma with metastasis. Acta Med Okayama 1998;42(1):1-6.
Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Mellon JK. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 2001;7(11):3450-6.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
